November 5, 2021
First HKSTP and AstraZeneca Co-Incubation Programme Incubatee – DotBio Pte Ltd
AstraZeneca Hong Kong (AZHK) and the Hong Kong Science and Technology Parks Corporation (HKSTP) are excited to announce the first incubatee of the HKSTP AZ Co-Incubation Programme - DotBio Pte Ltd (DotBio), a Singapore-based biopharmaceutical start-up focusing on next-generation multi-specific antibody drugs. The programme will support DotBio in its mission to develop integrated oncology solutions and accelerate innovation in oncology.
This co-incubation programme also aims to foster local biomedical technologies and enhance Hong Kong’s status as a leading biomedical innovation hub. DotBio’s Hong Kong subsidiary (DotBioHK Limited) has a proprietary humanized, stable Domain Therapeutic Antibody (DotBody) technology that will revolutionize multi-specific therapies, antibody-drug conjugates and cell therapies. The company currently possesses proprietary state-of-art DotBody and Fab phage display libraries, as well as numerous preclinical assets in the immuno-oncology field.
Dr Ignacio Asial, CEO and Founder of DotBio, said: “We are very honoured and excited to join the HKSTP AZ Co-Incubation Programme. This is a great opportunity for DotBio to work closely with the HKSTP and AstraZeneca teams, and accelerate the development of DotBody-based oncology therapies. We look forward to connecting with the global scientific and business community within the AstraZeneca network to bring more effective cancer therapies for patients who desperately need them.”
Carol Mui, General Manager of AstraZeneca Hong Kong, said: “Welcome DotBio to be the 1st Incubatee start-up! We are happy to connect talented entrepreneurs and teams to help build an international community for innovation and helping patients for better diagnosis and treatment.”
Ryan Bate, Scientific Partnering and Alliances Director of AstraZeneca International, said: “We are delighted to see this landmark reached with our partners DotBio & HKSTP! We believe that patient experiences and outcomes are our shared responsibility, and that innovation doesn’t happen in isolation. This is a perfect example of how the A.Catalyst Network brings together diverse stakeholders from across industry, geographical boundaries & disciplines to facilitate collaborative action, opening up new opportunities to enhance patient-enabled innovation.”
Professor W. John Kao, Head of Institute for Translational Research, said: “HKSTP and AZ join forces to support DotBio to translate innovative technologies to support the patient journey. ‘Oh, the places you'll go’."
About HKSTP AZ Co-Incubation Programme
This is the first oncology-related partnership launched by AstraZeneca Hong Kong and HKSTP. The plan would last for two years from 2021-2023. Participating startups will also become members of HKSTP Incu-Bio. For details about Incu-Bio, please visit https://www.hkstp.org/what-we-offer/incubation-and-acceleration-programmes/incubation/incu-bio/ .
This co-incubation programme also aims to foster local biomedical technologies and enhance Hong Kong’s status as a leading biomedical innovation hub. DotBio’s Hong Kong subsidiary (DotBioHK Limited) has a proprietary humanized, stable Domain Therapeutic Antibody (DotBody) technology that will revolutionize multi-specific therapies, antibody-drug conjugates and cell therapies. The company currently possesses proprietary state-of-art DotBody and Fab phage display libraries, as well as numerous preclinical assets in the immuno-oncology field.
Dr Ignacio Asial, CEO and Founder of DotBio, said: “We are very honoured and excited to join the HKSTP AZ Co-Incubation Programme. This is a great opportunity for DotBio to work closely with the HKSTP and AstraZeneca teams, and accelerate the development of DotBody-based oncology therapies. We look forward to connecting with the global scientific and business community within the AstraZeneca network to bring more effective cancer therapies for patients who desperately need them.”
Carol Mui, General Manager of AstraZeneca Hong Kong, said: “Welcome DotBio to be the 1st Incubatee start-up! We are happy to connect talented entrepreneurs and teams to help build an international community for innovation and helping patients for better diagnosis and treatment.”
Ryan Bate, Scientific Partnering and Alliances Director of AstraZeneca International, said: “We are delighted to see this landmark reached with our partners DotBio & HKSTP! We believe that patient experiences and outcomes are our shared responsibility, and that innovation doesn’t happen in isolation. This is a perfect example of how the A.Catalyst Network brings together diverse stakeholders from across industry, geographical boundaries & disciplines to facilitate collaborative action, opening up new opportunities to enhance patient-enabled innovation.”
Professor W. John Kao, Head of Institute for Translational Research, said: “HKSTP and AZ join forces to support DotBio to translate innovative technologies to support the patient journey. ‘Oh, the places you'll go’."
About HKSTP AZ Co-Incubation Programme
This is the first oncology-related partnership launched by AstraZeneca Hong Kong and HKSTP. The plan would last for two years from 2021-2023. Participating startups will also become members of HKSTP Incu-Bio. For details about Incu-Bio, please visit https://www.hkstp.org/what-we-offer/incubation-and-acceleration-programmes/incubation/incu-bio/ .